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Two new studies have shown that there is considerable crosstalk and cross-regulation of the Ephrin/VEGF
pathways in endothelial cells. These findings illustrate how EphrinB2 signaling and VEGF, in a cooperative
manner, induce VEGFR activation in endothelial cells and give new insight into how endothelial cell-mediated
construction of vessels is accomplished.Eph-ephrin signaling is well established
as the major regulator of cellular topog-
raphy during embryogenesis, vasculo-
genesis, and angiogenesis. This pathway
is involved in regulating a number of crit-
ical processes, including axon guidance,
and in many cases determining cell direc-
tion, shape, and orientation. Several
components of this family of ligands and
receptors have been associated with
cancer progression (Foo et al., 2006;
Kullander and Klein, 2002). Both ligands
(ephrins) and receptors (Eph) are classi-
fied into two groups, A and B, and A- or
B-type receptors have preference for A-
or B-type ligands, respectively, with a
certain degree of promiscuity and a few
known exceptions; e.g., EphA4 receptor
can bind both A- and B-type ligands,
and ephrin-A5 can bind to EphB2 in addi-
tion to all A-type receptors (Murai and
Pasquale, 2003).
Eph receptors are the largest family of
transmembrane tyrosine kinase recep-
tors, with a single transmembrane
domain, a ligand recognition site in the
extracellular region, and a cytoplasmic
domain that has a juxtamembrane short
sequence containing two conserved tyro-
sines, a tyrosine kinase domain, a sterile
a-motif (SAM), and aPDZbinding domain.
Ephrin ligands are also membrane-bound
proteins: A-type ephrins are GPI-linked
proteins, whereas B-type ephrins are
transmembrane proteins that contain
a cytoplasmic region that also includes
conserved tyrosine residues and a PDZ
domain (Kullander and Klein, 2002).
A couple of features distinguish this
otherwise conventional receptor kinase-
driven signaling pathway: one is that
both ligand and receptor are membrane-
bound, which imposes a requirement for
cell-cell interaction for the signal to take
place, instead of the long-range actionobserved for soluble/secreted ligands;
and the other is that this engagement
often results in the activation of both
receptor (forward signaling) and ligand
(reverse signaling), with distinct implica-
tions for each cell. Meeting of ligand and
receptor results in activation of signaling
cascades that mostly result in repulsion
stimuli between adjacent cells (Murai
and Pasquale, 2003), fundamental for
boundary formation and maintenance of
cell position. However, it can also occa-
sionally result in cell-cell attraction; this
dual role is dependent on the cell type
as well as the Eph:ephrin ratio gradient
(Hansen et al., 2004; Murai and Pasquale,
2003).
This Eph-ephrin bidirectional signaling
has been the focus of studies in the past
two decades, and two noteworthy recent
publications in Nature examine more
closely the role of ephrin-B2 in angio-
and lymphangiogenesis (Wang, et al.,
2010; Sawamiphak, et al., 2010). Ephrin-
B2 is specific to arterial endothelium and
considered a marker for vessel identity
from early embryogenesis; it is involved
in vascular remodeling and is upregulated
at sites of neovascularization, such as
tumors and wounds (Foo et al., 2006;
Wang et al., 1998). The activation of the
PDZ motif of ephrin-B2 has been shown
to be required for individual endothelial
cell contraction and expansion episodes,
and ephrin-B2 expression has been asso-
ciated with the progression and spread of
many human cancers. Upregulation of
ephrin-B2 alone also results in increased
motility of endothelial cells and has been
proposed to be in turn regulated by
VEGF (Bochenek et al., 2010). Further-
more, Vihanto and colleagues have shown
that ephrin-B2 expression is induced in
hypoxic skin, potentially in a HIF-1a-
dependent fashion (Vihanto et al., 2005).Cancer CellEphrin-B2 has long been recognized as
a key component of the signaling leading
to endothelial cell migration and new
vessel formation, probably in coordina-
tion with VEGF signaling. However,
tangible links between these two path-
ways have been missing. Some of this
void has just been filled with these two
independent findings, mechanistically
connecting ephrin-B2 and VEGF signaling
during angio- and lymphangiogenesis.
Sawamiphak and colleagues used two
ephrin-B2 mutants in their study, one
with five tyrosine residues in the cyto-
plasmic signaling domain changed to
phenylalanine, which thus impaired phos-
photyrosine-mediated signaling, and the
other with a deletion of a single Valine
residue in the PDZ binding region, which
restricted its interaction with PDZ-binding
proteins and inhibited PDZ reverse
signaling in the endothelium (Sawami-
phak et al., 2010). This latter modification
results in decreased filipodial extensions
in tip cells, shown to be a consequence
of failure to internalize and activate
VEGFR2. Their results show ephrin-B2
as a direct activator of VEGFR2, even in
the absence of VEGF-A, and possibly as
a cooperating partner with VEGF in the
signaling leading to tip cell extension
and vessel sprouting. This team also used
an orthotopic glioma model to appraise
the effect of ephrin-B2 PDZ domain inhibi-
tion in tumor angiogenesis and observed
a striking difference in tumor growth.
Tumor volume in mutant mice was less
than 25% of that seen in wild-type litter-
mates, a phenotype directly correlated
with a decreased, normalized tumor vas-
cularization and an accompanying lower
rate of sprouting and filipodia formation.
Moreover, they show that this role of eph-
rin-B2 appears to be specific to endothe-
lial cells.17, June 15, 2010 ª2010 Elsevier Inc. 533
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similarly bridges the reverse activation of
ephrin-B2 with the VEGF-dependent acti-
vation of VEGFR3 (Wang et al., 2010). The
developmental defects observed in
animals lacking endothelial ephrin-B2 are
consistent with defective endothelial cell
sprouting: embryos show edema and
hemorrhagic skin vasculature and smaller
and less complex retinal vasculature;
endothelial cells devoid of this ligand fail
to form protrusions and networks in
culture. These results were nicely comple-
mented with an endothelial gain-of-func-
tion model, which showed, in essence,
the opposite phenotype. Similarly to
what was observed for VEGFR2, the
VEGF-dependent activation and internali-
zation of VEGFR3 is compromised in the
absence of a functional endothelial eph-
rin-B2. VEGFR3 is the primary receptor
for VEGF-C, which is itself a critical factor
in lymphangiogenesis. Induction of either
ephrin-B2 or its preferred receptor
EphB4 is sufficient to induce VEGFR3
internalization, even though they fail to
induce its activation.
These discoveries are important, in that
they elucidate how these two signaling534 Cancer Cell 17, June 15, 2010 ª2010 Elspathways crosstalk during angiogenesis
and lymphangiogenesis, and make room
for the identification of other players in
what promises to be an intricate associa-
tion. Even though there is a manifest
cooperation between endothelial ephrin-
B2 and VEGF required for VEGFR activa-
tion, more work is needed to clarify what
ephrin-B2 effector (probably PDZ-
binding) protein(s) facilitate this functional
interaction.
Antiangiogenic therapies have been
explored as cancer treatments for some
time now, and although the ‘‘starvation’’
of tumors via direct VEGF signaling antag-
onism can result in tumor vasculature
regression, significant recent evidence
shows that these beneficial effects can
be merely transient, and may even result
in drug resistance, elevated invasion, and
increased metastasis (e.g., Pa`ez-Ribes
et al., 2009), with a much less than desir-
able impact on patient survival. The identi-
fication of other components of this evi-
dently very complex network of ligands,
receptors, and downstream activated
cascades is thus crucial to provide alter-
native or complementary strategies in the
development of antiangiogenic therapies.evier Inc.REFERENCES
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